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Mild cognitive impairment (MCI) is frequent in Parkinson’s disease (PD). Recently proposed criteria for MCI in PD (PD-MCI)
indicate level I diagnosis based on abbreviated assessment and level II based on comprehensive neuropsychological evaluation.The
study explored the sensitivity and specificity of the Italian versions of three neuropsychological tests for level I diagnosis of PD-
MCI.We recruited 100 consecutive PD patients. After screening for inclusion criteria, 43 patients were included.The sensitivity and
specificity of the Mini Mental State Examination (MMSE), the Montreal Cognitive Assessment (MoCA), and the Addenbrooke’s
Cognitive Examination Revised (ACE-R) in comparison to level II diagnosis of PD-MCI were examined. PD-MCI was diagnosed
(level II) in 51% of patients. Disease duration was significantly longer and PD motor scales were more severely impaired in MCI
group.The receiver-operator characteristics curve documented nonsignificant difference in the performance of the three tests, with
slight advantage of MMSE (corrected data). The time of administration favored MMSE. In Italian-speaking PD patients, MMSE
might represent a good screening tool for PD-MCI, because of the shorter time of administration and the performance comparable
to those of MoCA and ACE-R. Further studies are needed to validate the new PD-MCI criteria across different languages and
cultures.
1. Introduction
Cognitive impairment is frequent in Parkinson’s disease (PD)
[1], and the spectrum of cognitive dysfunction ranges from
mild cognitive impairment (MCI) to PD dementia (PD-D)
[2, 3].The diagnosis of PD-Dmay to some extent be straight-
forward [4], but recognizing MCI in PD (PD-MCI) is more
difficult. Cognitive deficits may occur early in PD course,
and they can be documented in up to a quarter of newly
diagnosed PD patients [5].The biological validity of PD-MCI
as a clinical entity is supported by converging morpholog-
ical, functional neuroimaging, neurophysiological, genetic,
and cerebrospinal fluid and histological data showing an
association between a number of neuropathophysiological
variables and cognitive impairment or cognitive decline in
nondemented PD patients [2].
Identifying PD-MCI is clinically important, as these
patients appear to be at increased risk for developing PD-
D [6], and they often present functional impairment and
have worse quality of life [2]. In the rehabilitation setting,
recognizing PD-MCI is very important, in that it may neg-
atively influence the outcome in patients undergoing motor
rehabilitation. Moreover, PD-MCI may itself represent a
target for cognitive training [7, 8], pharmacological treatment
[9], or their combination.
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A task force of theMovementDisorder Society (MDS) has
recently delineated diagnostic criteria for PD-MCI [10].These
criteria indicate a two-step process with level I (possible PD-
MCI) based on abbreviated assessment and level II diagnosis
based on comprehensive neuropsychological evaluation per-
mitting MCI subtyping [10], but they need to be validated,
as well as the proposed neuropsychological scales and tests.
A very recent study explored these criteria in a group of
PD patients and the accuracy of three neuropsychological
screening tests and found that none of them provided
good combined sensitivity and specificity for PD-MCI [11].
For most of the neuropsychological tests, translation and
validation across different languages and cultures are lacking,
and this may represent a problem when assessing PD-MCI
with level I criteria and a possible source of error when
transferring data from a given population/language to other
ones.
The present studywas aimed to explore the sensitivity and
specificity of the Italian versions of three neuropsychological
tests for level I diagnosis of PD-MCI, namely, theMiniMental
State Examination (MMSE) [12], the Montreal Cognitive
Assessment (MoCA) [13], and the Addenbrooke’s Cognitive
Examination Revised (ACE-R) [14], for all of which an Italian
translation and validation exist [15–18]. Data from the three
screening neuropsychological tests were compared to those
from full neuropsychological testing (level II) [10], which
represent the gold standard for MCI diagnosis.
2. Materials and Methods
2.1. Subjects. Our population sample was a group of 100
consecutive Italian PD patients. The study was carried out
in accordance with the principles of the Declaration of
Helsinki as revised in 2001 and approved by local ethics
committee. All patients gave signed informed consent prior
to inclusion in the study. Inclusion criteria were (1) diagnosis
of PD based on the UK PD Brain Bank Criteria [19];
(2) absence of PD-D [4]; (3) no other possible causes for
cognitive impairment (e.g., delirium, stroke or cerebrovas-
cular disease, head trauma, metabolic abnormalities, and
adverse effects of medication); (4) no other PD-associated
comorbid conditions (e.g., markedmotor impairment, severe
or unpredictablemotor fluctuations and/or dyskinesia, severe
anxiety, excessive daytime sleepiness, or psychosis) that may
have significantly influenced cognitive testing [10].
Depressionwas assessedwith the BeckDepression Inven-
tory II (BDI-II) [20] with a cutoff of 14 for the presence of
mild depression and a cutoff of 28 for severe depression [21].
Depression was not considered an exclusion criterion, except
if severe (i.e., patients with a BDI-II score>28were excluded),
because it may be found in around 35% of PD patients [22]
and including PD patients with mild to moderate depression
would have resulted in a more real-life scenario. The severity
of PDmotor symptoms and related impairment and disability
was measured with the Modified Hoehn and Yahr Staging
Scale [23] and the Unified Parkinson’s disease rating scale
[24]. Total daily levodopa equivalent dose was calculated for
each patient [25].
Assessed for eligibility
Eligible and included
More than one reason (n = 18)
Severe depression (n = 7)
Psychosis or delirium (n = 1)
Excessive daytime sleepiness (n = 1)
Severe motor ﬂuctuations or dyskinesia (n = 6)
Marked motor impairment (n = 4)
Adverse effects of medication (n = 2)
Stroke or cerebrovascular disease (n = 2)
Dementia (n = 16)
Excluded (n = 57)
(n = 43)
(n = 100)
Figure 1: Flow diagram of the study and reasons for patients’
exclusion.
After screening for inclusion criteria (Figure 1), 43
patients (27 males, 16 females, mean age 68.2±9.2, range 44–
88; mean education 8.5±2.9 years, range 4–13) were included
in the study. Demographic and clinical characteristics of
patients are reported in Table 1.
2.2. Neuropsychological Assessment. All patients underwent
the Italian versions of MMSE, MoCA, and ACE-R and a
full neuropsychological testing, which were performed by
different expert neuropsychologists, who were blinded to
each other’s results, on separate days at a similar time of the
day, and with the patient in the ON state. Given overlapping
items, the order of administration of the three screening tests
was pseudorandom to avoid bias in performance related to
fatigue, learning, or other effects secondary to order [11].
Since the ACE-R contains all the items of the MMSE, the
common items were not administered twice. The time taken
for administering each screening test and full neuropsycho-
logical testing was measured in each patient.
Full neuropsychological testing included at least two
types of neuropsychological testing for each of the five
following cognitive domains [10]. Attention and working
memory were examined with four tests, namely, digit span,
a subtest of the Wechsler memory scale [26], interference
memory task (10 sec and 30 sec) based on theBrown-Peterson
paradigm [27, 28], and trail making test (TMT) part A [29].
Executive functionwas explored with four tests, namely, TMT
part B [29], frontal assessment battery [30], phonemic fluency
test, and clock drawing test, the latter two being subtests of
the short neuropsychological examination version 2 (ENB-
2) [31]. Language was examined with four tests, namely,
the short form of the Boston naming test [32] and three
specific subtests of the neuropsychological examination of
aphasia [33]. Memory was explored with four tests, namely,
Rey’s auditory verbal learning test (immediate recall, delayed
Parkinson’s Disease 3
Table 1: Demographic and clinical characteristics of the patients.
Pt Sex Age (y) School (y) Duration (y) H-Y (1–5) Treatment and daily dosage Depression (yes/no)
1 F 44 12 5 1 PRX 4.5mg, RAS 1mg No
2 M 46 8 15 3 LD 600mg, APO 36mg, PRX 3mg Yes
3 M 51 13 10 2.5 LD 1150mg No
4 F 52 11 14 2 APO 84mg, CAB 9mg No
5 F 56 13 11 2.5 LD 500mg, APO 48mg, PRX 4.5mg Yes
6 F 57 13 10 2 LD 600mg, APO 52mg No
7 M 60 12 8 3 LD 500mg Yes
8 M 60 8 20 3 LD 750mg Yes
9 M 61 8 5 1 RAS 1mg Yes
10 M 61 13 21 2.5 LD 950mg No
11 F 63 10 4 1.5 PRX 3mg Yes
12 F 64 5 2 1.5 LD 400mg Yes
13 F 65 5 10 2.5 LD 700mg, PRX 1.5mg, RAS 1mg No
14 F 67 13 10 2 LD 1000mg, PRX 4.5mg No
15 M 67 10 5 1 LD 400mg No
16 M 67 8 1 1 None Yes
17 M 68 8 3 1.5 LD 400mg Yes
18 M 68 8 22 2.5 LD 975mg Yes
19 M 68 10 21 3 LD 1250mg Yes
20 M 68 8 23 2.5 LD 1150mg No
21 M 69 8 24 3 LD 950mg Yes
22 M 69 5 4 3 LD 850mg No
23 M 70 10 24 4 LD 1200mg Yes
24 F 70 3 10 1.5 LD 800mg No
25 M 72 8 4 1 LD 350mg, ROP 8mg No
26 F 72 12 12 2.5 LD 550mg, APO 42mg No
27 M 72 8 12 2.5 LD 1250mg No
28 F 73 5 5 1 LD 250mg, SEL 10mg No
29 M 73 13 7 3 LD 1250mg, ROT 10mg No
30 M 74 8 4 3 LD 700mg, PRX 3mg No
31 M 75 8 6 3 LD 600mg, ROP 16mg No
32 M 75 5 3 1 ROP 16mg, SEL 10mg No
33 M 75 5 20 3 LD 1100mg, ROP 12mg No
34 M 75 5 10 2.5 LD 800mg, PRX 4.5mg Yes
35 F 75 5 5 2 LD 300mg, ROP 16mg No
36 M 76 8 20 2.5 LD 1150mg, PRX 3mg No
37 M 76 6 10 2 LD 900mg, PRX 3mg No
38 M 76 5 25 3 LD 1250mg No
39 F 76 8 8 2 LD 1000mg Yes
40 M 76 13 11 2 LD 750mg Yes
41 F 79 5 4 2 LD 300mg No
42 F 83 5 4 2 LD 500mg Yes
43 F 88 4 1 1.5 LD 400mg No
Average 68.2 8.3 10.5 2.2
SD 9.3 3.0 7.3 0.8
Pt: patient; school: education (years); duration: disease duration (years); H-Y: Modified Hoehn and Yahr Staging Scale (range 1–5); SD: standard deviation;
APO: apomorphine; CAB: cabergoline; LD: levodopa (dosage corrected according to the eventual use of COMT-inhibitors); PRX: pramipexole; RAS: rasagiline;
ROP: ropinirole; ROT: rotigotine; SEL: selegiline.
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Table 2: Characteristics of patients, according to the diagnosis and subtype of PD-MCI (MDS Task Force level II criteria).
No PD-MCI (𝑛 = 21) PD-MCI (𝑛 = 22) 𝑝 Single-domainPD-MCI (𝑛 = 8)
Multiple-domain
PD-MCI (𝑛 = 14) 𝑝
Age 67.5 ± 11.2 68.9 ± 7.2 n.s. 65.5 ± 7.7 70.8 ± 6.2 n.s.
Sex (M/F) 12/9 15/7 n.s. 7/1 8/6 n.s.
School (y) 8.7 ± 3.1 8.3 ± 2.8 n.s. 9.3 ± 2.6 7.6 ± 2.8 n.s.
Duration (y) 7.8 ± 5.3 12.8 ± 8.1 0.03 13.1 ± 8.6 11.4 ± 8.1 n.s.
H-Y (1–5) 1.9 ± 0.7 2.5 ± 0.6 0.014 2.3 ± 0.8 2.6 ± 0.5 n.s.
UPDRS-III (0–108) 23.3 ± 8.9 30.2 ± 8.4 0.02 27.5 ± 10.2 31.5 ± 9.0 n.s.
Treatment
LD (yes/no) 17/4 20/2 n.s. 7/1 13/1 n.s.
DA (yes/no) 12/9 7/15 n.s. 2/6 5/9 n.s.
MAO-I (yes/no) 4/17 1/21 n.s. 0/8 1/13 n.s.
Total LED (mg) 821 ± 413 889 ± 394 n.s. 893 ± 439 888 ± 384 n.s.
Depression (yes/no) 8/13 9/13 n.s. 3/5 6/8 n.s.
School: education (years); duration: disease duration (years); H-Y:ModifiedHoehn and Yahr Staging Scale (range 1–5); UPDRS-III: Unified Parkinson’s Disease
Rating Scale part III (range 0–108); LD: levodopa; DA: dopamine agonist; MAO-I: monoamine oxidase inhibitors; LED: levodopa equivalent dose (daily).
recall) [34], and two prose recall subtest (immediate recall,
delayed recall) derived fromENB-2 [31].Visuospatial function
was examined with two tests, namely, Benton’s judgment of
line orientation [35] and the geometrical figures copying test,
a subtest of the mental deterioration battery [36].
The impairment on basic activities of everyday life
(BADL) and instrumental activities of everyday life (IADL)
was explored with specific questionnaires [37, 38].
2.3. PD-MCI Diagnosis. The diagnosis of PD-MCI was made
according to the MDS Task Force level II criteria [10]. They
included (1) gradual decline, in the context of established
PD, in cognitive ability reported by either the patient or
informant or observed by the clinician, consisting of at
least 1 item of the IADL scale; (2) cognitive deficits that
are not sufficient to interfere significantly with functional
independence, although subtle difficulties on complex func-
tional tasks may be present, as documented by normal BADL
scale; (3) impairment in at least two neuropsychological tests,
represented by either two impaired tests in one cognitive
domain (single-domain PD-MCI) or one impaired test in
two different cognitive domains (multiple-domain PD-MCI).
Impaired performance on a neuropsychological test was
defined as a score that was at least 1.5 standard deviations
(SDs) below the age-adjusted mean from normative data [11].
According to the MDS Task Force criteria, significant decline
on serial cognitive testing or from estimated premorbid level
may be used instead of normative data [10], but we did not
use these alternative criteria, because the former would have
required repeated full neuropsychological testing with the
risk of learning bias and because of the difficulties found in
applying the latter (see Section 4) [11].
2.4. Statistical Analysis. All tests were carried out with the
IBM SPSS version 20.0 and the Stata 11.0 statistical packages.
The normality of variable distribution was analyzed with the
Skewness-Kurtosis test. Continuous variables were explored
with ANOVA and post hoc 𝑡-test with Bonferroni’s correc-
tion. Homogeneity of variance was analyzed with Levene’s
test.The data were transformed (logarithmic transformation)
before submitting them to ANOVA in case of an inequality
in the variances. The nonparametrical Mann-Whitney 𝑈
test was applied in case the distribution was not normal.
Pearson’s 𝜒2 test with Yates’ correction for continuity was
applied to dichotomous variables. Sensitivity and specificity
of the MMSE (raw score and score corrected for age, sex,
and education),MoCA (raw and corrected score), andACE-R
were calculated across all possible cutoff scores below which
an individual would be classified as having PD-MCI. The
area under the receiver-operator characteristics (ROC) curve
(AUC) was calculated and compared across the three tests
and the AUC 95% confidence intervals (CIs) were generated.
𝑝 < 0.05 (two-tailed) was taken as the significance threshold
for all the tests.
3. Results
According to the MDS Task Force level II criteria [10], PD-
MCI was diagnosed in 22 patients (51%). Eight out of the
22 (36%) PD-MCI patients were classified as single-domain
MCI, with five of them showing impairment in executive
function and three with impaired memory. The other 14
patients (64%) were classified as multiple-domain MCI.
Among multiple-domain MCI cases, attention and working
memory was impaired in 9 patients, executive function in
14, memory in 8, language in 2, and visuospatial function
in 1. Demographic and clinical variables according to the
presence or absence ofMCI and theMCI subtype (i.e., single-
domain versus multiple-domain) are reported in Table 2.
Disease duration was significantly longer in patients with
MCI (12.8 ± 8.1 years) than in those without MCI (7.8 ± 5.3
years, 𝑝 = 0.03; Table 2). PD motor and impairment scales
were more severely impaired in MCI group (H-Y: 2.5 ± 0.6;
UPDRS-III: 30.2 ± 8.4) than in patients without MCI (H-Y:
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1.9±0.7, 𝑝 = 0.014; UPDRS-III: 23.3±8.9, 𝑝 = 0.02; Table 2).
The other variables did not differ between the two groups.
None of the demographic and clinical variables significantly
differed according to the MCI subtype (Table 2).
3.1. Comparison between the Screening Tests. TheROC curves
for the three screening tests (raw and corrected data) are
illustrated in Figure 2. The AUC was 0.84 (95% CI: 0.72–
0.97) for the MMSE (raw data), 0.88 (95% CI: 0.78–0.98) for
the MMSE (corrected data), 0.80 (95% CI: 0.66–0.93) for the
MoCA (raw data), 0.79 (95% CI: 0.66–0.93) for the MoCA
(corrected data), and 0.81 (95%CI: 0.68–0.94) for the ACE-R.
None of the pair-wise comparisons between AUC estimates
were statistically significant.
The sensitivity and specificity of the three tests for
detecting PD-MCI across different cutoff scores are reported
in Tables 3 and 4.
3.2. Screening Cutoff Values. For raw MMSE data, the
lowest cutoff value with sensitivity >0.80 was 29.5 (sen-
sitivity = 0.96, specificity = 0.62). When using corrected
MMSE data, the lowest cutoff value with sensitivity >0.80
was 28.6 (sensitivity = 0.86, specificity = 0.71). For raw
MoCA data, the lowest cutoff value with sensitivity >0.80
was 24.5 (sensitivity = 0.82, specificity = 0.67). When
analyzing corrected MoCA data, the lowest cutoff value
with sensitivity >0.80 was 25.5 (sensitivity = 0.82, speci-
ficity = 0.67). For ACE-R, the lowest cutoff value with
sensitivity >0.80 was 86.0 (sensitivity = 0.82, specificity =
0.67).
3.3. Diagnostic Cutoff Values. For raw MMSE data, the high-
est cutoff value with specificity >0.80 was 28.5 (sensitivity =
0.73, specificity = 0.81). When examining corrected MMSE
data, the highest cutoff value with specificity >0.80 was
28.0 (sensitivity = 0.73, specificity = 0.81). For raw MoCA
data, the highest cutoff value with specificity >0.80 was 21.5
(sensitivity = 0.55, specificity = 0.90). When using corrected
MoCA data, the highest cutoff value with specificity >0.80
was 22.5 (sensitivity = 0.55, specificity = 0.86). When
analyzing ACE-R findings, the highest cutoff value with
specificity >0.80 was 77.5 (sensitivity = 0.59, specificity =
0.81).
3.4. Timing for Administering Screening Tests and Full Neu-
ropsychological Testing. The average time for the adminis-
tration of the screening tests was 7.8 ± 1.4min for MMSE,
12.3 ± 3.2min for MoCA, and 18.4 ± 2.9min for ACE-R. Full
neuropsychological testing required 52.3 ± 7.1min.
4. Discussion
We have explored the sensitivity and specificity of the Italian
versions of three screening tests for recognizing PD-MCI
in comparison to full neuropsychological testing. Our data
documented that the performances of the three tests were
similar and that they could achieve a limited trade-off
between sensitivity and specificity, with a slight advantage of
MMSE and the use of corrected data.
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Figure 2: Receiver-operator characteristics (ROC) curves for the
three screening tests (raw and corrected data).
The screening tests we examined were chosen because,
to the best of our knowledge, they were the only ones with
the availability of a validated Italian version at the time
when the study was designed. None of them could reach
combined sensitivity and specificity >0.80 at any cutoff value.
The analysis of ROC curves for the screening scales showed a
larger AUC and the best sensitivity-specificity profile for the
corrected MMSE score. In particular, a cutoff of 28.6 resulted
in sensitivity = 0.86 and specificity = 0.71, while a cutoff of
28.0 was associated in sensitivity = 0.73, and specificity = 0.81.
The other scales performed slightly worse, but the difference
between the ROC curves was not significant.
A number of previous studies compared different screen-
ing tests for assessing cognitive functions and/or early cog-
nitive deficit in PD patients [5, 39], with conflicting results
in terms of the best profile of sensitivity and specificity
between them. The use of MMSE as a screening instrument
in PD has been challenged because it does not specifically
test subcortical executive function, which is impaired early in
PD patients [40]. Some studies documented that MMSE has
low sensitivity in detectingMCI and cognitive impairment in
PD [41, 42], in particular when compared to MoCA [39, 43–
45]. At variance, other authors reported that MMSE might
be useful in detecting cognitive deterioration in early PD
[46]. Data on the use of ACE-R as a screening tool for PD-
MCI are controversial [47], but a previous version was found
to be a good test for evaluating MCI [48] and dementia
[49, 50] in PD patients. A reason for these discrepancies
might be that ACE-R includes an assessment by domains
and its abilities may not be completely comparable to that
of MMSE and MoCA, which represent true screening scales.
Moreover, MMSE and ACE-R share some common items,
and the total points of ACE-R (100 points) differ from that
of MMSE and MoCA (30 points). However, the comparison
of AUCs instead of cutoffs should have avoided the difference
in total points among screening tests to represent a bias.
Comparison between the present results and those from
most of previous studies is however difficult, because only
a few of them used a comprehensive neuropsychological
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Table 3: Sensitivity and specificity of MMSE and MoCA for
detecting PD-MCI at different cutoff values.
Cutoff Sensitivity Specificity
MMSE
Raw data
<24.5 0.05 0.95
<25.5 0.23 0.95
<26.5 0.32 0.95
<27.5 0.50 0.90
<28.5 0.73 0.81
<29.5 0.96 0.62
Corrected data
<22.5 0.05 1.00
<23.2 0.09 1.00
<23.7 0.14 1.00
<24.3 0.18 1.00
<25.0 0.27 1.00
<25.2 0.32 1.00
<25.4 0.36 1.00
<25.7 0.41 1.00
<26.0 0.46 1.00
<26.2 0.50 1.00
<26.3 0.50 0.95
<26.4 0.50 0.91
<26.6 0.55 0.91
<26.8 0.59 0.91
<27.0 0.64 0.91
<27.2 0.68 0.86
<27.6 0.73 0.86
<28.0 0.73 0.81
<28.4 0.77 0.76
<28.6 0.86 0.71
<29.4 0.95 0.62
MoCA
Raw data
<15.0 0.05 1.00
<16.5 0.09 1.00
<17.5 0.18 0.95
<19.0 0.27 0.95
<20.5 0.41 0.90
<21.5 0.55 0.90
<22.5 0.59 0.76
<23.5 0.77 0.71
<24.5 0.82 0.67
<25.5 0.82 0.52
<26.5 0.91 0.33
<27.5 1.00 0.29
<28.5 1.00 0.14
<30.0 1.00 0.00
Corrected data
<16.0 0.05 1.00
<17.5 0.09 1.00
Table 3: Continued.
Cutoff Sensitivity Specificity
<18.5 0.18 0.95
<20.0 0.27 0.95
<21.5 0.46 0.90
<22.5 0.55 0.86
<23.5 0.59 0.76
<24.5 0.77 0.71
<25.5 0.82 0.67
<26.5 0.86 0.52
<27.5 0.91 0.33
<28.5 1.00 0.29
<29.5 1.00 0.05
MMSE:MiniMental State Examination; MoCA:Montreal Cognitive Assess-
ment; PD-MCI: mild cognitive impairment in Parkinson’s disease.
Table 4: Sensitivity and specificity of ACE-R for detecting PD-MCI
at different cutoff values.
Cutoff Sensitivity Specificity
<62.5 0.05 1.00
<66.5 0.09 1.00
<69.5 0.14 0.95
<73.5 0.27 0.95
<75.5 0.46 0.90
<76.5 0.50 0.86
<77.5 0.59 0.81
<78.5 0.64 0.76
<80.0 0.68 0.76
<82.5 0.73 0.76
<84.5 0.73 0.71
<86.0 0.82 0.67
<87.5 0.86 0.62
<89.0 0.91 0.62
<90.5 0.91 0.43
<91.5 0.91 0.38
<92.5 1.00 0.38
<93.5 1.00 0.29
<94.5 1.00 0.24
<95.5 1.00 0.19
<96.5 1.00 0.14
<97.5 1.00 0.09
<98.5 1.00 0.05
<100.0 1.00 0.00
ACE-R: Addenbrooke’s Cognitive Examination Revised; PD-MCI: mild
cognitive impairment in Parkinson’s disease.
evaluation and standard criteria to detect and diagnose MCI.
A couple of recent studies applied the new MDS criteria for
MCI and yielded contrasting results, in that one documented
limited sensitivity-specificity profile for both MMSE and
MoCA [11], while the other reported high sensitivity ofMoCA
for predicting PD-MCI [51].
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Other neuropsychological scales, such as the Mattis
dementia rating scale [48, 52, 53], the Cambridge cognitive
assessment [54], the cognitive linguistic quick test [55], the
PD cognitive rating scale [56], and the SCOPA cognition
[57], have been demonstrated to be helpful in exploring early
cognitive decline in PD [10], but the absence of an Italian
version impeded their exploration as a screening tool for
PD-MCI in our PD patients sample. What is more, the long
administration time of these scales (i.e., up to 25–45󸀠) is not
suitable for a screening procedure in the clinical setting.
Our data favor the correction for age, sex, and education
when scoring MMSE, in that corrected MMSE data yielded
a larger AUC and slightly better sensitivity-specificity profile
than raw ones. At variance, correcting MoCA did not change
the performance of the test. However, pair-wise statistical
comparisons between ROC curves did not show any signif-
icant difference between them. In the clinical setting, MMSE
correction is reasonable especially for older and less educated
patients.
We recorded the time taken for administering the three
screening scale, and this variable favored the MMSE (7.8 ±
1.4min) compared to the MoCA (12.3 ± 3.2min) and the
ACE-R (18.4±2.9min). According to these combined figures
(i.e., similar sensitivity-specificity profile, shorter time of
administration), it is reasonable to prefer the use of MMSE
in the setting of a busy clinic.
A number of factors may contribute to cognitive dys-
function in PD patients and lead to a false positive diag-
nosis of PD-MCI. All the possible contributing factors were
considered and our strict inclusion criteria, which resulted
in the exclusion of approximately half of the patients,
should have reduced this bias. Drugs with possible effect on
cognition represented an exclusion criterion, and the total
LED was similar between patients with and without MCI.
As a consequence, pharmacological effects should not have
influenced our findings. Depression has been documented
to be more frequent in PD-MCI patients in comparison to
those without MCI [58], but this was not the case in our
sample. We excluded only patients with severe depression
according to the BDI-II, becausemild tomoderate depression
is a common feature of PD and exclusion of all depressed
patients might have resulted in a non-real-life scenario. We
may argue that depression should not have been a bias factor
in the present study.
PD patients with MCI had significantly longer disease
duration and more severe motor impairment and disability,
according to the H-Y and UPDRS-III scales. This finding
is in accordance with some previous reports [58] but in
contrast with other ones [11]. Differences in the sampling of
PD patients across different studies, depending on different
settings (e.g., primary care versus referral centre) or different
populations, are the most likely reasons for this discrepancy.
The analysis of MCI subtypes indicated a prevalence of
multidomain PD-MCI in comparison to single-domain.This
finding is in accordance with previous reports using new
MDS criteria [11, 59]. We could not document any difference
in clinical variables between single- and multidomain PD-
MCI patients, but the small samples might have impeded the
recognition of small differences between the two groups. In
accordance with previous studies [5, 7], we documented a
high prevalence of executive alterations in our PD sample.
This finding may stem from the use of four tests for this
cognitive domain, which may have resulted in a higher
likelihood of falling in two of them [60]. However, this
potential bias effect seems not to be major, because the upper
limit (maximum probability) for detecting impairment on
a test was found to stabilize at two tests in the executive
functions domain and did not increasewith three or four tests
[60].
When applying the MDS level II diagnostic criteria for
PD-MCI [10], impairment on a neuropsychological test was
defined as a score that was at least 1.5 SD below the age-
adjusted normative data [11]. We avoided the use of the
alternative criterion of a significant decline on serial cognitive
testing [10], because of the lack of previous neuropsychologi-
cal testing in the majority of our patients. For what concerns
the other alternative criteria of a decline from estimated
premorbid level [10], this was also not used for a number of
reasons.They include the lack of any indication on how to use
tests of premorbid intellectual functioning [10], the absence
of a validated Italian version of the Wechsler test of adult
reading [10], and the previous evidence of the ineffectiveness
of the Italian version of the alternative national adult reading
test for the estimation of premorbid reading ability [61].
In a previous study, the number of patients diagnosed as
PD-MCI with level II criteria varied consistently (i.e., from
33% to 79%) by applying different criteria for impairment
on a neuropsychological test [11], and this might represent
an important source of uncertainty when applying level II
criteria. Similarly, varying cutoff values for single tests had a
large influence on the percentage of PD-MCI patients in the
same population [62].
Limitations of the present study include the small sample
and the high prevalence of PD-MCI. MCI was found in
51% patients in our PD sample, while cross-sectional studies
documented that the prevalence of MCI ranges from 20
to 30% in PD [42, 58]. However, our sample is too small
to provide a good approximation of the prevalence of the
condition in the general population, and theremay have been
some bias due to the strict selection criteria.The present data
should be confirmed in a larger PD patients group before
generalizing our conclusions.
Another limitation is the absence of follow-up data.
Serial testing of PD-MCI patients documented that a similar
proportion of them might either progress to PD-D or revert
to normal cognition (i.e., approximately 20%) after one year
[63]. Reasons for this apparently paradoxical finding might
include comorbidities, measurement errors, learning effects
due to repeated neuropsychological testing, and improved
cognition after initiation of symptomatic treatment [63], in
addition to suboptimal treatment of motor symptoms at the
time of first testing, motor fluctuations, or drug side effects.
BADL and IADL were evaluated with questionnaires [37,
38] that are not PD-specific, because, to the best of our
knowledge, there is no Italian version of any disease-specific
scale, such as the Parkinson’s disease cognitive functional
rating scale [64]. We think that this point does not represent
a major bias, because the questionnaires were used to group
8 Parkinson’s Disease
patients as having PD-MCI or not and not to quantitatively
measure impairment on BADL and IADL.
5. Conclusions
Our data might be helpful in the clinical and the neuroreha-
bilitation setting, because cognitive impairment is common
in PD, PD-MCI may progress to PD-D, and both these con-
ditionsmay have a negative impact on function, quality of life,
and caregiver burden [43]. Identification and intervention
at the earliest stage of PD-MCI is a crucial unmet need for
the overall care of PD patients [10]. MMSE might represent
a good tool for screening cognition throughout all stages
of PD, because of the short time of administration and the
sensitivity-specificity profile comparable to those of MoCA
and ACE-R. Follow-up serial testing might be necessary in
case of confounding factors. Complete neuropsychological
testing, however, still represents the gold standard for a
diagnosis of PD-MCI.
Future studies should better explore the reliability of
level I and level II MDS criteria for MCI and incorporate
biomarkers of cognitive dysfunction [2, 10].
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